Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 40,000 Shares

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer sold 40,000 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the transaction, the chief executive officer directly owned 6,000 shares in the company, valued at $266,580. This trade represents a 86.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Ian Mortimer also recently made the following trade(s):

• On Monday, December 8th, Ian Mortimer sold 10,830 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $45.73, for a total transaction of $495,255.90.
• On Friday, December 5th, Ian Mortimer sold 14,375 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $45.03, for a total transaction of $647,306.25.
• On Friday, November 28th, Ian Mortimer sold 97 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $45.01, for a total transaction of $4,365.97.

Xenon Pharmaceuticals Stock Performance

Xenon Pharmaceuticals stock traded down $0.33 during mid-day trading on Friday, reaching $44.49. 1,166,387 shares of the company were exchanged, compared to its average volume of 708,094. The firm has a market cap of $3.44 billion, a P/E ratio of -11.44 and a beta of 0.97. The business has a fifty day moving average of $42.59 and a 200 day moving average of $38.21. Xenon Pharmaceuticals Inc. has a 12-month low of $26.74 and a 12-month high of $46.60.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.01. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.81) earnings per share. Sell-side analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC acquired a new position in shares of Xenon Pharmaceuticals in the 2nd quarter valued at $25,000. Elevation Point Wealth Partners LLC purchased a new position in shares of Xenon Pharmaceuticals in the second quarter worth about $32,000. Danske Bank A S purchased a new stake in Xenon Pharmaceuticals in the third quarter valued at approximately $32,000. Aster Capital Management DIFC Ltd acquired a new stake in Xenon Pharmaceuticals during the 3rd quarter valued at approximately $39,000. Finally, Osaic Holdings Inc. increased its stake in shares of Xenon Pharmaceuticals by 541.4% in the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,034 shares during the period. 95.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

XENE has been the topic of a number of recent analyst reports. Chardan Capital upgraded shares of Xenon Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Needham & Company LLC reiterated a “buy” rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, November 4th. William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Tuesday, October 7th. Royal Bank Of Canada lifted their price target on shares of Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. upped their price target on Xenon Pharmaceuticals from $57.00 to $60.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $54.64.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.